Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Perampanel in ALS
NCT03377309Phase 2Terminated
- Sponsor
- American University of Beirut Medical Center
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of perampanel in amyotrophic lateral sclerosis (ALS), sponsored by American University of Beirut Medical Center. Started Dec 2019; status: terminated.
02
Drugs
perampanel
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03377309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377309.